Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee Osteoarthritis

Inclusion Criteria: * If a woman of childbearing potential, the study participant must not be pregnant at the time of consent and must take contraceptive measures to prevent a pregnancy while actively participating in the study * The study participant may be of any gender or ethnic background. * Must experience knee pain at least weekly for at least 3 months. * Must have failed a minimum of 6 weeks of first line, conservative therapy * Demonstrated clinical and radiographic evidence of OA diagnosis * Grade 2, 3, or 4 Kellgren-Lawrence score in one knee. * Normal or within protocol approved limits of laboratory blood and urinalysis tests * Must be suitable for cellular therapy per the Investigator's opinion * Must be suitable for liposuction per the Investigator's opinion * Must possess the cognitive ability to understand the investigational nature of this clinical trial and voluntarily provide consent for study participation Exclusion Criteria: * Evidence of OA in the contralateral knee with a Kellgren-Lawrence score greater than 2 * If a woman of child-bearing potential, the study participant must not be pregnant or attempt to become pregnant while actively taking part in the study. * Steroid injection in either knee within 60 days of providing informed consent * The subject must not be diagnosed with any of the following diseases at the time of consent: * Osteonecrosis * Active autoimmune disease * Serious cardiac condition * Psychotic Diseases * Epilepsy * Uncontrolled diabetes * Prescribed immunosuppressive therapy at the time of consent * Evidence of cancer at the time of consent * History of alcohol or substance abuse * Regular smoker at the time of consent * Received experimental medication or participated in another clinical study within 60 days of providing informed consent * Concurrent diseases or circumstances that the Investigator judges to be a potential risk to patient health or a confounding variable in the assessment of study endpoints.